NEW YORK (GenomeWeb) – Roche will collaborate with the Garvan Institute of Medical Research in Sydney to develop technology for targeted next-gen sequencing-based epigenomic analysis, the company said today.

Under the terms of the two-year discovery agreement, researchers at the Garvan Institute will use Roche NimbleGen's SeqCap Target Enrichment System to develop new methods for accurately analyzing regions of the epigenome.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.